Literature DB >> 7769725

Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus.

N L Letvin1, J Li, M Halloran, M P Cranage, E W Rud, J Sodroski.   

Abstract

Prior infection with a nef-deleted simian immunodeficiency virus (SIV) protects macaques not only against a homologous pathogenic SIV challenge but also against challenge with a chimeric SIV expressing a human immunodeficiency virus type 1 env gene (SHIV). Since this SHIV is itself nonpathogenic, we sought to explore the use of a nonpathogenic SHIV as a live, attenuated AIDS virus vaccine. Four cynomolgus monkeys infected for greater than 600 days with a chimeric virus composed of SIVmac 239 expressing the human immunodeficiency virus type 1 HXBc2 env, tat, and rev genes were challenged intravenously with 100 animal infectious doses of the J5 clone of SIVmac 32H, an isolate derived by in vivo passage of SIVmac 251. Three of the four monkeys became infected with SIVmac. This observation underlines the difficulty, even with a live virus vaccine, in protecting against an AIDS virus infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769725      PMCID: PMC189207          DOI: 10.1128/JVI.69.7.4569-4571.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  7 in total

1.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

Review 2.  Vaccines against human immunodeficiency virus--progress and prospects.

Authors:  N L Letvin
Journal:  N Engl J Med       Date:  1993-11-04       Impact factor: 91.245

Review 3.  Primate models for HIV vaccines.

Authors:  A M Schultz; S L Hu
Journal:  AIDS       Date:  1993       Impact factor: 4.177

4.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

6.  Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants.

Authors:  E W Rud; M Cranage; J Yon; J Quirk; L Ogilvie; N Cook; S Webster; M Dennis; B E Clarke
Journal:  J Gen Virol       Date:  1994-03       Impact factor: 3.891

7.  A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes.

Authors:  H Tsubota; C I Lord; D I Watkins; C Morimoto; N L Letvin
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

  7 in total
  6 in total

1.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.

Authors:  K A Reimann; J T Li; G Voss; C Lekutis; K Tenner-Racz; P Racz; W Lin; D C Montefiori; D E Lee-Parritz; Y Lu; R G Collman; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines.

Authors:  B R Gundlach; S Reiprich; S Sopper; R E Means; U Dittmer; K Mätz-Rensing; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.

Authors:  Elias G Argyris; Geethanjali Dornadula; Giuseppe Nunnari; Edward Acheampong; Chune Zhang; Ketti Mehlman; Roger J Pomerantz; Hui Zhang
Journal:  Virology       Date:  2006-07-21       Impact factor: 3.616

6.  Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.

Authors:  Kristina Abel; Lara Compton; Tracy Rourke; David Montefiori; Ding Lu; Kristina Rothaeusler; Linda Fritts; Kristen Bost; Christopher J Miller
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.